4642 J ournal of Medicinal Chemistry, 1996, Vol. 39, No. 23
Thaisrivongs et al.
(10) Kempf, D. J .; Marsh, K. C.; Fino, L. C.; Bryant, P.; Craig-
Kennard, A.; Sham, H. L.; Zhao, C.; Vasavanonda, S.; Kohlbren-
ner, W. E.; Wideburg, N. E.; Saldivar, A.; Green, B. E.; Herrin,
T.; Norbeck, D. W. Design of Orally Bioavailable, Symmetry-
based Inhibitors of HIV Protease. Bioorg. Med. Chem. 1994, 2,
847-858.
(11) Kempf, D. J .; Marsh, K. C.; Denissen, J . F.; McDonald, E.;
Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C.
H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati,
W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner,
J . J .; Leonard, J . M.; Norbeck, D. W. ABT-538 is a Potent
Inhibitor of Human Immunodeficiency Virus Protease and has
High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci.
U.S.A. 1995, 92, 2484-2488.
(12) Vacca, J . P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel,
S. L.; Darke, P. L.; Zugay, J .; Quintero, J . C.; Blahy, O. M.; Roth,
E.; Sardana, V. V.; Schlabach, A. J .; Graham, P. I.; Condra, J .
H.; Gotlib, L.; Holloway, M. K.; Lin, J .; Chen, I.-W.; Vastag, K.;
Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J . R. L-735,-
524: An Orally Bioavailable Human Immunodeficiency Virus
Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994,
91, 4096-4100.
(25) Vara Prasad, J . V. N.; Para, K. S.; Lunney, E. A.; Ortwine, D.
F.; Dunbar, J . B., J r.; Ferguson, D.; Tummino, P. J .; Hupe, D.;
Tait, B. D.; Domagala, J . M.; Humblet, C.; Bhat, T. N.; Liu, B.;
Guerin, D. M. A.; Baldwin, E. T.; Erickson, J . W.; Sawyer, T. K.
Novel Series of Achiral, Low Molecular Weight, and Potent
HIV-1 Protease Inhibitors. J . Am. Chem. Soc. 1994, 116, 6989-
6990.
(26) Lunney, E. A.; Hagen, S. E.; Domagala, J . M.; Humblet, C.;
Kosinski, J .; Tait, B. D.; Warmus, J . S.; Wilson, M.; Ferguson,
D.; Hupe, D.; Tummino, P. J .; Baldwin, E. T.; Bhat, T. N.; Liu,
B.; Erickson, J . W. A Novel Nonpeptide HIV-1 Protease Inhibi-
tor: Elucidation of the Binding Mode and Its Application in the
Design of Related Analogs. J . Med. Chem. 1994, 37, 2664-2677.
(27) Wlodawer, A.; Erickson, J . W. Structure-based Inhibitors of
HIV-1 Protease. Annu. Rev. Biochem. 1993, 62, 543-585.
(28) Appelt, K. Crystal Structures of HIV-1 Protease-Inhibitor Com-
plexes. Perspect. Drug Discovery Des. 1993, 1, 23-48.
(29) Hamilton, H. W.; Tait, B. D.; Gajda, C.; Hagen, S. E.; Ferguson,
D.; Lunney, E. A.; Pavlovsky, A.; Tummino, P. J . 6-Phenyl-
6-alkylamido-5,6-dihydro-2H-pyran-2-ones: Novel HIV Protease
Inhibitors. Bioorg. Med. Chem. 1996, 6, 719-724.
(30) Trost, B. M. New Rules of Selectivity: Allylic Alkylations
Catalyzed by Palladium. Acc. Chem. Res. 1980, 13, 385-393.
(31) Moreno-Manas, M.; Prat, M.; Ribas, J .; Virgili, A. Palladium
Catalyzed Allylic C-Alkylation of Highly Acidic and Enolic
Heterocyclic Substrates: Tetronic Acid and Triacetic Acid Lac-
tone. Tetrahedron Lett. 1988, 581-584. Moreno-Manas, M.;
Ribas, J .; Virgili, A. Palladium-Catalyzed C-Alkylation of the
Highly Acidic and Enolic Triacetic Acid Lactone. Mechanism
and Stereochemistry. J . Org. Chem. 1988, 53, 5328-5335.
(32) Tsuji, J .; Yuhara, M.; Minato, M.; Yamada, H.; Sato, F.;
Kobayashi, Y. Palladium-Catalyzed Regioselective Reactions of
Silyl-Substituted Allylic Carbonate and Vinyl Epoxide. Tetra-
hedron Lett. 1988, 343-346. Tsuji, J . Selectivities in Organic
Reactions via π-Allyl Palladium Complexes. Pure Appl. Chem.
1989, 61, 1673-1679.
(13) Lam, P. Y.-S.; J adhav, P. K.; Eyermann, C. J .; Hodge, C. N.;
Ru, Y.; Bacheler, L. T.; Meek, J . L.; Otto, M. J .; Rayner, M. M.;
Wong, Y. N.; Chang, C.-H.; Weber, P. C.; J ackson, D. A.; Sharpe,
T. R.; Erickson-Vitanen, S. Rational Design of Potent, Bioavail-
able, Non-peptide Cyclic Urea as HIV Protease Inhibitors.
Science 1994, 263, 380-384.
(14) Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Vitanen,
S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic
Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and
Dogs. Biopharm. Drug Dispos. 1994, 15, 535-544.
(15) Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.;
Talley, J . J .; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr,
J . J .; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W.
C.; Stegeman, R. A. Discovery of a Novel Class of Potent HIV-1
Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isos-
tere. J . Med. Chem. 1993, 36, 288-291.
(16) Bryant, M. HIV Protease Inhibitors: Action to Efficacy. Inhibi-
tor SC-55389a presented at Session 46 (I) at the 34th ICAAC,
Orlando, FL, 1994.
(33) Tomasselli, A. G.; Olsen, M. K.; Hui, J . O.; Staples, D. J .; Sawyer,
T. K.; Heinrikson, R. L.; Tomich, C.-S. C. Substrate Analogue
Inhibition and Active Site Titration of Purified Recombinant
HIV-1 Protease. Biochemistry 1990, 29, 264-269.
(17) Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B.
G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease
in Complex with VX-478, a Potent and Orally Bioavailable
Inhibitor of the Enzyme. J . Am. Chem. Soc. 1995, 117, 1181-
1182.
(18) Patick, A. K.; Mo, H.; Markowitz, M.; Appelt, K.; Wu, B.; Musick,
L.; Kalish, V.; Kaldor, S.; Reich, S.; Ho, D.; Webber, S. Antiviral
and Resistance Studies of Ag 1343, an Orally Bioavailable
Inhibitor of Human Immunodeficiency Virus Protease. Anti-
microb. Agents Chemother. 1996, 40, 292-297.
(19) Mimoto, T.; Imai, J .; Kisanuki, S.; Enomoto, H.; Hattori, N.;
Akaju, K.; Kiso, Y. Kynostatin KNI-227 and -272, Highly Potent
Anti-HIV Agents: Conformationally Constrained Tripeptide
Inhibitors of HIV Protease Containing Allophenylnorstatine.
Chem. Pharm. Bull. 1992, 40, 2251-2253.
(20) Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-
T.; Howe, W. J .; Yang, C.-P.; Strohbach, J . W.; Turner, S. R.;
McGrath, J . P.; Bohanon, M. J .; Lynn, J . C.; Mulichak, A. M.;
Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J .; Moon, J . B.;
Ruwart, M. J .; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga,
R. J .; Schwende, R. J .; Howard, G. M.; Padbury, G. E.; Toth, L.
N.; Zhao, Z.; Koeplinger, K. A.; Kakuk, T. J .; Cole, S. L.; Zaya,
R. M.; Piper, R. C.; J effrey, P. Structure-Based Design of HIV
Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-
pyrones as Non-peptidic Inhibitors. J . Med. Chem. 1994, 37,
3200-3204.
(34) Mildner, A. M.; Rothrock, D. J .; Leone, J . W.; Bannow, C. A.;
Lull, J . M.; Reardon, I. M.; Sarchich, J . L.; Howe, W. J .; Tomich,
C. C.; Smith, C. W.; Heinrickson, R. L.; Tomasselli, A. G. The
autolysis Sites and Generation of a Stable Mutant and Retained
Kinetic Properties. Biochemistry 1994, 33, 9405-9413.
(35) Mulichak, A. M.; Hui, J . O.; Tomasselli, A. G.; Heinrikson, R.
L.; Curry, K. A.; Tomich, C.-S.; Thaisrivongs, S.; Sawyer, T. K.;
Watenpaugh, K. D. The Crystallographic Structure of the
Protease from Human Immunodeficiency Virus Type 2 with Two
Synthetic Peptide Transition State Analog Inhibitors. J . Biol.
Chem. 1993, 268, 13103-13109.
(36) Howard, A. J .; Gilliland, G. L.; Finzel, B. C.; Poulos, T. L.;
Ohlendorf, D. H.; Salemme, F. R. The Use of an Imaging
Proportional Counter in Macromolecular Crystallography. J .
Appl. Crystallogr. 1987, 20, 383-387.
(37) Watenpaugh, K. D. Conformational Energy as a Restraint in
Refinement. In Proceeding of the Molecular Dynamics Work-
shop, 1984, Chapel Hill; Hermans, J ., Ed.; Polycrystal Book:
Western Springs, IL, 1985; pp 77-80.
(38) Sack, J . S. CHAIN: a Crystallographic Modelling Program. J .
Mol. Graph. 1988, 6, 224-225.
(39) Brunger, A. X-PLOR: A System for X-ray Crystallography and
NMR; Yale University Press: New Haven, CT, 1992.
(40) Bernstein, F. C.; Koetzle, T. F.; Williams, G. J . B.; Meyer, E. F.;
Brice, M. D.; Rogers, J . B.; Kennard, O.; Shimanouchi, T.;
Tasumi, M. The Protein Data Bank: A Computer-based Archival
File for Macromolecular Structures. J . Mol. Biol. 1977, 112,
535-542.
(41) Hall, S. R.; Stewart, J . M., Eds. Xtal 3.0 Reference Manual;
Universities of Western Australia, Perth and Maryland: College
Park, MD, 1990.
(42) Tomasselli, A. G.; Howe, W. J .; Sawyer, T. K.; Wladawer, A.;
Heinrikson, R. L. The Complexities of AIDS: An Assessment of
the HIV Protease as a Therapeutic Target. Chim. Oggi 1991,
9, 6-27.
(21) Skulnick, H. I.; J ohnson, P. D.; Howe, W. J .; Tomich, P. K.;
Chong, K.-T.; Watenpaugh, K. D.; J anakiraman, M. N.; Dolak,
L. A.; McGrath, J . P.; Lynn, J . C.; Horng, M.-M.; Hinshaw, R.
R.; Zipp, G. L.; Ruwart, M. J .; Schwende, F. J .; Zhong, W.-Z.;
Padbury, G. E.; Dalga, R. J .; Shiou, L.; Possert, P. I.; Rush, B.
D.; Wilkinson, K. F.; Howard, G. M.; Toth, L. N.; Williams, M.
G.; Kakuk, T. J .; Cole, S. L.; Zaya, R. M.; Thaisrivongs, S.;
Aristoff, P. A. Structure-Based Design of Sulfonamide Substi-
tuted Non-peptidic HIV Protease Inhibitors. J . Med. Chem.
1995, 38, 4968-4971.
(22) Bourinbaiar, A. S.; Tan, X.; Nagorny, R. Effect of the Oral
Anticoagulant, Warfarin, on HIV-1 Replication and Spread.
AIDS 1993, 7, 129-130.
(23) Tummino, P. J .; Ferguson, D.; Hupe, L.; Hupe, D. Competitive
Inhibition of HIV-1 Protease by 4-Hydroxy-benzopyran-2-ones
and by 4-Hydroxy-6-phenylpyran-2-ones. Biochem. Biophys. Res.
Commun. 1994, 200, 1658-1664.
(24) Tummino, P. J .; Ferguson, D.; Hupe, D. Competitive Inhibition
of HIV-1 Protease by Warfarin Derivatives. Biochem. Biophys.
Res. Commun. 1994, 201, 290-294.
(43) Mossmann, T. Rapid Colorimetric Assay for Cellular Growth and
Survival: Application to Proliferation and Cytotoxicity Assays.
J . Immunol. Methods 1983, 65, 55-63.
(44) Chong, K.-T.; Pagano, P. J .; Hinshaw, R. R. Bisheteroarylpip-
erazine Reverse Transcriptase Inhibitor in Combination with
3′-Azido-3′-Deoxythymidine or 2′,3′-Dideoxycytidine Synergisti-
cally Inhibits Human Immunodeficiency Virus Type 1 Replica-
tion In Vitro. Antimicrob. Agents Chemother. 1994, 38, 288-293.
J M960228Q